Predict your next investment

Corporation
roswellpark.org

See what CB Insights has to offer

Investments

2

Partners & Customers

8

About Roswell Park Cancer Institute

Roswell Park Cancer Institute, founded in 1898, is the nation's first cancer center and offers quality cancer care.

Roswell Park Cancer Institute Headquarter Location

Elm and Carlton Streets

Buffalo, New York, 14263,

United States

877-275-7724

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Roswell Park Cancer Institute News

Curiato announces CEO transition and expansion of leadership team to accelerate growth

May 4, 2021

WATERLOO, ONT., May 4, 2021 – Curiato Inc. today announced a CEO transition with the appointment  of Dr. Thomas P. Stewart to the role of Interim CEO. The expansion of the leadership  team will enable Curiato to accelerate its commercialization timeline and scale-up. Dr. Stewart is an industry veteran who is the founder of the National Pressure Injury  Advisory Panel (NPIAP) and has served in various senior leadership roles with Gaymar  Industries, Stryker, Milsport Medical, and Board positions with the Roswell Park Cancer  Institute and the Buffalo Niagara Partnership. “I am thrilled to be joining as Interim CEO,” said Dr. Stewart. “The progress made under  the founding team has been tremendous. I am honoured in the trust placed in me to  continue this tradition and also for the opportunity to lead our team on the next leg of what  promises to be an exciting journey. Having served as an advisor to the company for the  past 2 years, I strongly believe in the potential of patient data and insights – derived from  the surface of the bed – to tackle some of health care’s most significant and costliest  challenges.”  Along with the CEO transition, the company is also expanding its leadership team with  the addition of Jim Price as VP Product and Dr. Cynthia Sylvia as VP Clinical Affairs. Jim  is an experienced product development and marketing executive who had previous  product leadership roles with Hillrom, Gaymar Industries, Extremiti 3D, and Tridien  Medical. Dr. Sylvia is an experienced clinical leader with deep expertise in the nursing  and wound care space with industry experience through roles with Stryker and Gaymar Industries. Collectively, the new leadership team appointments have the industry  credibility and experience to transition Curiato from a validated startup to be recognized  as a market player with its first use case of providing clinical decision support to improve  pressure injury prevention practices. “Curiato had a successful year in 2020 during which our company achieved its major  milestones – positive clinical validation, Health Canada licensing, FDA registration, and  our first commercial deployment,” said Moazam Khan, Co-founder. “With emphasis  shifting to scale-up as well as clinical and commercial execution going forward, these  leadership changes best position us for future success. Please join me in extending a  warm welcome to Tom, Jim, and Cindy.”   The Board of Directors, with guidance from our shareholders and support from Dr.  Stewart, will lead the search for a permanent CEO. “The co-founders remain active on the Board of Directors and continue to serve within Curiato. These changes are a  testament to their entrepreneurialism and pragmatism,” adds Dr. Stewart. Investor Relations Contact  About Curiato  Curiato, Inc. is a commercial-stage digital health company and leader in the new category  of smart surface monitoring. Our lead product offering – PI CONNECTTM – delivers  actionable patient insights from the bed surface which can be used for clinical decision  support. Our platform combines a smart bed cover – which converts any medical mattress  into a smart bed – and predictive analytics to harness a new category of quality, objective  patient data & insights. Through our clinical research to date we have evidence validating  four patient insights – mobility, moisture, temperature, and posture. Our lead offering for  pressure injuries is in-market and registered for sale with Health Canada & FDA. Our  long-term strategy is to use our patient insights to create an ecosystem of clinical decision  support apps for pressure injuries, infectious disease, cardiology, burns, robotic surgery,  and more. About Dr. Thomas P. Stewart  https://www.linkedin.com/in/dr-thomas-stewart-5337699/  Safe Harbour Statement  This press release contains “forward-looking information” within the meaning of  applicable securities legislation. All information contained herein that is not clearly  historical in nature may constitute forward- looking information. Generally, such forward looking information can be identified by the use of forward-looking terminology such as  “plans”, “expects”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or  variations thereof or statements that certain actions, events or results “may”, “could”,  “would”, “might” occur. Without limiting the generality of the foregoing, the business model and go-to-market strategy sections of this presentation constitute forward-looking  information. Although Curiato, Inc. (the “Company”) has attempted to identify important  factors that could cause actual results to differ materially from those contained in the  forward-looking information, there may be other factors that cause results to differ from  what the Company anticipated, estimated or intended, including without limitation: (i) the  general global markets and economic conditions; (ii) the possibility that our business  model may not gain market acceptance if at all; (iii) competition faced by the Company in  securing experienced personnel and financing; (iv) risks related to regulatory issues; (v)  risks related to potential conflicts of interest; (vi) the reliance on key personnel; (vii) the  proposed investment will not enable us to reach the milestones; (viii) the risk of intellectual  property litigation; (ix) risk management and (x) other circumstances beyond the  Company’s control. Such forward-looking information has been provided for the purpose  of assisting investors in understanding the Company’s business and operations and may  not be appropriate for other purposes. Accordingly, readers should not place undue  reliance on forward-looking information. Forward-looking information is made as of the  date of this presentation. The Company neither makes any representations or warranties  as to the accuracy of forward-looking information nor undertakes to update such forward looking information except in accordance with applicable securities legislation. Share:

Roswell Park Cancer Institute Investments

2 Investments

Roswell Park Cancer Institute has made 2 investments. Their latest investment was in OmniSeq as part of their Series B on April 4, 2018.

CBI Logo

Roswell Park Cancer Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/12/2018

Series B

OmniSeq

Yes

3

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/12/2018

Round

Series B

Other Investors

Company

OmniSeq

Subscribe to see more

Amount

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

3

10

Roswell Park Cancer Institute Acquisitions

2 Acquisitions

Roswell Park Cancer Institute acquired 2 companies. Their latest acquisition was Cancer Care & Hematology of Niagara on October 19, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/19/2015

Acquired

1

1/1/2012

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/19/2015

1/1/2012

Investment Stage

Spinoff / Spinout

Companies

Subscribe to see more

Valuation

Total Funding

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

Roswell Park Cancer Institute Partners & Customers

8 Partners and customers

Roswell Park Cancer Institute has 8 strategic partners and customers. Roswell Park Cancer Institute recently partnered with Lumeda on June 6, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

6/25/2020

Licensee

Lumeda

United States

Lumeda Enters License Agreement with Roswell Park Comprehensive Cancer Center.

Rocky Hill , Connecticut -- June 25 , 2020 -- Lumeda Inc. , a biophotonics systems company formed to advance photodynamic therapy for treating cancer , today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo , New York .

1

1/8/2020

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/15/2019

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/8/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/28/2015

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/25/2020

1/8/2020

4/15/2019

2/8/2019

4/28/2015

Type

Licensee

Client

Vendor

Partner

Vendor

Business Partner

Lumeda

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Lumeda Enters License Agreement with Roswell Park Comprehensive Cancer Center.

Rocky Hill , Connecticut -- June 25 , 2020 -- Lumeda Inc. , a biophotonics systems company formed to advance photodynamic therapy for treating cancer , today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo , New York .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.